Two years after going public through an $18 million IPO, a Philadelphia-based biopharmaceutical firm has reached a deal for a reverse merger with a California firm.
Two years after going public through an $18 million IPO, a Philadelphia-based biopharmaceutical firm has reached a deal for a reverse merger with a California firm.
